Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 3/20 | 0.66 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.54 |
| ▸ | YARS1 | P54577 | 2/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.49 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.48 |
| ▸ | NPPA | P01160 | 1/20 | 0.48 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 1/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29370934 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL29386049 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL29371447 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL338635 | 1.00 | LNPEP (0.66) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL29405990 | 0.99 | LNPEP (0.65) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL30090915 | 0.97 | LNPEP (0.64) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL30523264 | 0.96 | LNPEP (0.63) | LNPEPERAP2SLC7A5NPY1RNPY2R | |
| SCHEMBL29406227 | 0.96 | LNPEP (0.61) | LNPEPERAP2SLC7A5YARS1NPY1R | |
| SCHEMBL30931517 | 0.95 | LNPEP (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R | |
| SCHEMBL30118045 | 0.95 | LNPEP (0.62) | LNPEPERAP2NPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 230 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025067293-A1 | HELICASE AND USE THEREOF | 北京齐碳科技有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119709689-A | Helicase and application thereof | 北京齐碳科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119080875-A | Gadolinium-based contrast agent modified by amino acid group blocking and application thereof | 兰州大学 | 2024-12-06 | — | — | CN | claimed |
| CN-118878633-A | Application of multi-target peptide in preparing analgesic drug | 南通大学 | 2024-11-01 | — | — | CN | claimed |
| CN-118047840-A | Opioid receptor linear peptide and triazole cyclized peptide analogue, and preparation and application thereof | 兰州大学 | 2024-05-17 | — | — | CN | claimed |
| CN-114088853-B | Characteristic peptide segment of soman poisoning and identification method of soman poisoning | 中国人民解放军61699部队 | 2024-04-19 | — | — | CN | claimed |
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-10-19 | — | — | US | claimed |
| CN-116870184-A | Self-assembled material for improving atherosclerosis as well as preparation method and application thereof | 国家纳米科学中心 | 2023-10-13 | — | — | CN | claimed |
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| CN-116457028-A | Novel CXCR4 targeting compounds | 省卫生服务机构 | 2023-07-18 | — | — | CN | claimed |
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-04-13 | — | — | US | claimed |
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) | 2022-12-08 | — | — | US | claimed |
| CN-114984255-A | Radionuclide-labeled PSMA-alpha v beta 3 double-target couplet and application thereof | 苏州大学 | 2022-09-02 | — | — | CN | claimed |
| EP-4041213-A1 | PSMA-TARGETING IMAGING AGENTS | The Cleveland Clinic Foundation (US) | 2022-08-17 | — | — | EP | claimed |
| EP-3980439-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | Szegedi Tudományegyetem (HU) | 2022-04-13 | — | — | EP | claimed |
| US-11040108-B2 | Amino acid- and peptide-steroid conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2021-06-22 | — | — | US | claimed |
| US-7052872-B1 | Bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-0087751-B1 | WATER-SOLUBLE PEPTIDES FROM VERY POORLY SOLUBLE AMINO ACIDS | PFRIMMER KABI GMBH & CO. KG (DE) | 1985-05-29 | — | — | EP | claimed |
| EP-0087751-A2 | Water-soluble peptides from very poorly soluble amino acids | PFRIMMER KABI GMBH & CO. KG (DE) | 1983-09-07 | — | — | EP | claimed |
| CN-121137079-B | Large Ma Shitong synthetase | 中国农业大学 | 2026-05-15 | — | — | CN | disclosed |
| US-12613191-B2 | Multiplexed Raman molecular imaging | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260109682-A1 | NOVEL COMPOUNDS AND THE USE FOR PROMOTING HAIR GROWTH OR INHIBITING INFLAMMATORY DISORDERS THEREOF | CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY (TW) | 2026-04-23 | — | — | US | disclosed |
| EP-4684030-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2026-01-28 | — | — | EP | disclosed |
| EP-4665839-A1 | CELL CULTURE MEDIA | Merck Patent GmbH (DE) | 2025-12-24 | — | — | EP | disclosed |
| US-20250346648-A1 | MAGE A4 T CELL RECEPTORS | MEDIGENE IMMUNOTHERAPIES GMBH (DE) | 2025-11-13 | — | — | US | disclosed |
| EP-4631516-A2 | MAGE A4 T CELL RECEPTORS | Medigene Immunotherapies GmbH (DE) | 2025-10-15 | — | — | EP | disclosed |
| US-12421485-B2 | Cell culture sheet assembly for large-capacity incubator, and large-capacity incubator comprising same | AMOGREENTECH CO., LTD. (KR) | 2025-09-23 | — | — | US | disclosed |
| US-12411124-B2 | System for sequencing biopolymers | UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION (US) | 2025-09-09 | — | — | US | disclosed |
| US-12344654-B2 | Mage A4 T cell receptors | MEDIGENE IMMUNOTHERAPIES GMBH (DE) | 2025-07-01 | — | — | US | disclosed |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | disclosed |
| WO-2025109003-A1 | P-CADHERIN LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| EP-3946621-B1 | MAGE A4 T CELL RECEPTORS | MEDIGENE IMMUNOTHERAPIES GMBH (DE) | 2025-05-21 | — | — | EP | disclosed |
| CN-119931966-A | BsBacD enzyme mutant, enzyme composition and preparation method of tyrosine dipeptide | 深圳瑞德林生物技术有限公司 | 2025-05-06 | — | — | CN | disclosed |
| US-20250138016-A1 | METHODS FOR THE DETECTION AND TREATMENT OF OVARIAN CANCER | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2025-05-01 | — | — | US | disclosed |
| WO-2025067293-A1 | HELICASE AND USE THEREOF | 北京齐碳科技有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-119709689-A | Helicase and application thereof | 北京齐碳科技有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-114599796-B | Biopolymer Sequencing System | 通用测序技术公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-119080875-A | Gadolinium-based contrast agent modified by amino acid group blocking and application thereof | 兰州大学 | 2024-12-06 | — | — | CN | disclosed |
| WO-2024227957-A2 | METHOD OF DEPROTECTING AT LEAST ONE D-AMINO ACID AND/OR D-AMINO ACID DERIVATIVE PROTECTED FUNCTIONAL GROUP | Martin-Luther-Universität Halle-Wittenberg (DE) | 2024-11-07 | — | — | WO | disclosed |
| CN-118878633-A | Application of multi-target peptide in preparing analgesic drug | 南通大学 | 2024-11-01 | — | — | CN | disclosed |
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| CN-111602822-B | Liver fat synthesis inhibitor | 不二制油集团控股株式会社 | 2024-10-01 | — | — | CN | disclosed |
| CN-118580335-A | MAGE A4T cell receptor | 基因医疗免疫疗法有限责任公司 | 2024-09-03 | — | — | CN | disclosed |
| WO-2024170622-A1 | CELL CULTURE MEDIA | MERCK PATENT GMBH (DE) | 2024-08-22 | — | — | WO | disclosed |
| US-20240263161-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | UNIVERSITY OF COPENHAGEN (DK) | 2024-08-08 | — | — | US | disclosed |
| US-20240173442-A1 | COMBINATION THERAPY | HOFFMANN-LA ROCHE INC. | 2024-05-30 | — | — | US | disclosed |
| CN-114126716-B | MAGE A4T cell receptor | 基因医疗免疫疗法有限责任公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-118047840-A | Opioid receptor linear peptide and triazole cyclized peptide analogue, and preparation and application thereof | 兰州大学 | 2024-05-17 | — | — | CN | disclosed |
| CN-117940585-A | Methods for identifying responsiveness to fibroblast growth factor receptor 1 inhibitor therapy | 科隆大学 | 2024-04-26 | — | — | CN | disclosed |
| EP-4347624-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | University of Copenhagen (DK) | 2024-04-10 | — | — | EP | disclosed |
| CN-110418837-B | Culture medium comprising oligopeptides | 赢创运营有限公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117701633-A | Method for regulating high mannose sugar type antibody in CHO cell, CHO cell and application thereof | 上海凯莱英生物技术有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240082437-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | HOFFMANN-LA ROCHE INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240085335-A1 | MULTIPLEXED RAMAN MOLECULAR IMAGING | UNIVERSITY OF SOUTHERN CALIFORNIA | 2024-03-14 | — | — | US | disclosed |
| CN-117683660-A | Lactobacillus bulgaricus and application thereof | 北京科拓恒通生物技术股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-109922818-B | CXCR4 antagonists and methods of use | 主线生物科学公司 | 2024-02-20 | — | — | CN | disclosed |
| CN-117551198-A | Nanometer antibody for resisting human and mouse B7-H3 and application thereof | 常州市第一人民医院 | 2024-02-13 | — | — | CN | disclosed |
| JP-2024018924-A | GLP-1 SECRETION PROMOTING COMPOSITION | 国立大学法人北海道大学 | 2024-02-08 | — | — | JP | disclosed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | disclosed |
| EP-4277668-A1 | COMBINATION THERAPY | F. Hoffmann-La Roche AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| EP-4277705-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. Hoffmann-La Roche AG (CH) | 2023-11-22 | — | — | EP | disclosed |
| CN-107660150-B | IL-18 binding proteins (IL-18 BP) and antibodies in inflammatory diseases | AB2生物股份有限公司 | 2023-10-24 | — | — | CN | disclosed |
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | Enlitisa (Shanghai) Pharmaceutical Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
| CN-116870184-A | Self-assembled material for improving atherosclerosis as well as preparation method and application thereof | 国家纳米科学中心 | 2023-10-13 | — | — | CN | disclosed |
| CN-116829593-A | Dividing antibodies that bind to cancer cells and target radionuclides to said cells | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| EP-4247426-A2 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-09-27 | — | — | EP | disclosed |
| CN-114984255-B | Radionuclide-labeled PSMA-alpha v beta 3 double-target coupling body and application thereof | 苏州大学 | 2023-09-26 | — | — | CN | disclosed |
| CN-116744981-A | combination therapy | 豪夫迈·罗氏有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-115044590-B | Application of p53 gene mutant and protein expressed by same in preparation of medicines for diagnosing and treating hypertrophic cardiomyopathy | 昆明理工大学 | 2023-08-15 | — | — | CN | disclosed |
| CN-116457028-A | Novel CXCR4 targeting compounds | 省卫生服务机构 | 2023-07-18 | — | — | CN | disclosed |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | EAGLE RESOLUTE INVESTMENT LLC | 2023-06-08 | — | — | US | disclosed |
| CN-116200385-A | dsRNA for inhibiting rhizoctonia solani AG4 related genes and application thereof | 河北农业大学 | 2023-06-02 | — | — | CN | disclosed |
| US-20230159612-A1 | MAGE A4 T CELL RECEPTORS | REGENERON PHARMACEUTICALS, INC. | 2023-05-25 | — | — | US | disclosed |
| EP-4178985-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. Hoffmann-La Roche AG (CH) | 2023-05-17 | — | — | EP | disclosed |
| EP-4171621-A1 | C825 EXPRESSING IMMUNE CELLS AND DIAGNOSTIC USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-05-03 | — | — | EP | disclosed |
| EP-4157293-A1 | ANTI-GD2 SADA CONJUGATES AND USES THEREOF | Memorial Sloan Kettering Cancer Center (US) | 2023-04-05 | — | — | EP | disclosed |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2023-02-14 | — | — | US | disclosed |
| US-11566256-B2 | Polynucleotides and polypeptides in plants | MENDEL BIOTECHNOLOGY, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| WO-2022253998-A1 | PEPTIDES WITH MUCIN-BINDING PROPERTIES | UNIVERSITY OF COPENHAGEN (DK) | 2022-12-08 | — | — | WO | disclosed |
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | SZTE TTC ZÁRTKÖRUEN MUKÖDO RÉSZVÉNYTÁRSASÁG (HU) | 2022-12-08 | — | — | US | disclosed |
| WO-2022211624-A1 | TAILOR-MADE FUNCTIONALIZED SELF-ASSEMBLED PEPTIDE (NANO)FIBERS AND HYDROGELS, AND METHODS, USES AND KITS RELATED THERETO | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2022-10-06 | — | — | WO | disclosed |
| CN-115044590-A | Application of p53 gene mutant and protein expressed by same in preparation of medicine for diagnosing and treating hypertrophic cardiomyopathy | 昆明理工大学 | 2022-09-13 | — | — | CN | disclosed |
| CN-114984255-A | Radionuclide-labeled PSMA-alpha v beta 3 double-target couplet and application thereof | 苏州大学 | 2022-09-02 | — | — | CN | disclosed |
| US-20220267463-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | HOFFMANN-LA ROCHE INC. (US) | 2022-08-25 | — | — | US | disclosed |
| WO-2022157674-A1 | MULTIPLEXED RAMAN MOLECULAR IMAGING | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022152656-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. HOFFMANN-LA ROCHE AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| WO-2022152701-A1 | COMBINATION THERAPY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| CN-114599796-A | Biopolymer sequencing system | 通用测序技术公司 | 2022-06-07 | — | — | CN | disclosed |
| WO-2022108976-A2 | ANTI-GPA33 MULTI-SPECIFIC ANTIBODIES AND USES THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-05-27 | — | — | WO | disclosed |
| EP-3997130-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | F. Hoffmann-La Roche AG (CH) | 2022-05-18 | — | — | EP | disclosed |
| EP-3980439-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | Szegedi Tudományegyetem (HU) | 2022-04-13 | — | — | EP | disclosed |
| CN-114341188-A | Antibodies that bind to cancer cells and target radionuclides to said cells | 豪夫迈·罗氏有限公司 | 2022-04-12 | — | — | CN | disclosed |
| EP-3320923-B1 | FLUORESCENT IMAGING AGENTS | VISEN MEDICAL INC (US) | 2022-04-06 | — | — | EP | disclosed |
| US-20220091094-A1 | A System for Sequencing Biopolymers | UNIVERSAL SEQUENCING TECHNOLOGY CORPORATION | 2022-03-24 | — | — | US | disclosed |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | DEBIOPHARM RESEARCH & MANUFACTURING S.A. (CH) | 2022-03-03 | — | — | US | disclosed |
| CN-114126716-A | MAGE A4T cell receptor | 基因医疗免疫疗法有限责任公司 | 2022-03-01 | — | — | CN | disclosed |
| US-20200197389-A1 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-06-25 | — | — | US | disclosed |
| EP-3634405-A1 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | The Regents of The University of California (US) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018209307-A1 | METHODS FOR DETECTING DYSBIOSIS AND TREATING SUBJECTS WITH DYSBIOSIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-11-15 | — | — | WO | disclosed |
| EP-1638510-B1 | MULTIVALENT CARRIERS OF BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS INC (US) | 2015-09-02 | — | — | EP | disclosed |
| EP-1720575-B1 | THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES | IMMUNOMEDICS INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-20140343865-A1 | Biomarkers for Kidney Cancer and Methods Using the Same | METABOLON, INC. | 2014-11-20 | — | — | US | disclosed |
| EP-2788763-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | Metabolon, Inc. (US) | 2014-10-15 | — | — | EP | disclosed |
| EP-1546204-B1 | CHIMERIC AND HUMANIZED ANTI-GRANULOCYTE MN-3 ANTIBODY AND USES THEREOF | IMMUNOMEDICS INC (US) | 2013-09-18 | — | — | EP | disclosed |
| CN-1668335-B | Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) | IMMUNOMEDICS INC | 2013-06-19 | — | — | CN | disclosed |
| WO-2013086365-A2 | BIOMARKERS FOR KIDNEY CANCER AND METHODS USING THE SAME | METABOLON, INC. (US) | 2013-06-13 | — | — | WO | disclosed |
| EP-1487879-B1 | BISPECIFIC ANTIBODY POINT MUTATIONS FOR ENHANCING RATE OF CLEARANCE | IMMUNOMEDICS INC (US) | 2012-12-26 | — | — | EP | disclosed |
| EP-1506018-B1 | DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT(S) | IMMUNOMEDICS INC (US) | 2012-12-12 | — | — | EP | disclosed |
| EP-1372718-B1 | PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8268312-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2012-09-18 | — | — | US | disclosed |
| EP-1546203-B1 | ALPHA-FETOPROTEIN IMMU31 ANTIBODIES AND FUSION PROTEINS AND METHODS OF USE THEREOF | IMMUNOMEDICS INC (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8188239-B2 | Multivalent carriers of bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20120107235-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8158573-B2 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | IMMUNOMEDICS, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20120063993-A1 | THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES | IMMUNOMEDICS, INC. (US) | 2012-03-15 | — | — | US | disclosed |
| US-8097252-B2 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8084029-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2011-12-27 | — | — | US | disclosed |
| US-20110229407-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| US-20110223645-A1 | Multivalent Carriers of Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-8017736-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2011-09-13 | — | — | US | disclosed |
| EP-1587550-B1 | METHODS AND COMPOSITIONS FOR ADMINISTERING THERAPEUTIC AND DIAGNOSTIC AGENTS | IMMUNOMEDICS INC (US) | 2011-07-27 | — | — | EP | disclosed |
| EP-2345673-A1 | Humanized anti-granulocyte MN-3 antibody and uses thereof | Immunomedics, Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-7951921-B2 | Multivalent carriers of bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-7951369-B2 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | IMMUNOMEDICS, INC. (US) | 2011-05-31 | — | — | US | disclosed |
| US-20110117010-A1 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents | IMMUNOMEDICS, INC. (US) | 2011-05-19 | — | — | US | disclosed |
| US-7943343-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| EP-2301581-A1 | Production and use of novel peptide-based agents for use with B1-specific antibodies | Immunomedics, Inc. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-7914787-B2 | Provide inter alia a bi-specific antibody or antibody fragment having one arm that specifically binds a targeted tissue and one other arm that specifically binds a targetable conjugate that can be modified for use in a wide variety of diagnostic and therapeutic applications | IMMUNOMEDICS, INC. (US) | 2011-03-29 | — | — | US | disclosed |
| US-7892547-B2 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7820164-B2 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| US-7776311-B1 | Immunological reagents for therapeutic use, in radioimmunotherapy (RAIT), and diagnostic use, in radioimmunodetection (RAID) and magnetic resonance imaging; conjugated drug as antiinflammatory, or anticarcinogenic agents; drug targets; tissue-targeted therapy | IMMUNOMEDICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-20100202961-A1 | D-AMINO ACID PEPTIDES | IMMUNOMEDICS, INC. | 2010-08-12 | — | — | US | disclosed |
| US-20100196989-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20100158802-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100158803-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100136626-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1089766-B1 | USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS AND THERAPY | IMMUNOMEDICS INC (US) | 2010-03-17 | — | — | EP | disclosed |
| US-7670804-B2 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7666415-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20100008855-A1 | Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies | IMMUNOMEDICS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-7641891-B2 | For the treatment and diagnosis of various cancers including carcinoma, gastrointestinal, colorectal, colon or ovarian cancer; colon-specific antigen-p mucin (CSAp) antigen | IMMUNOMEDICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090274649-A1 | Bispecific Antibody Point Mutations for Enhancing Rate of Clearance | IMMUNOMEDICS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090252731-A1 | Multivalent Carriers of Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090246131-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090238757-A1 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents | IMMUNOMEDICS, INC. (US) | 2009-09-24 | — | — | US | disclosed |
| US-20090185974-A1 | Chimeric, Human and Humanized Anti-Granulocyte Antibodies and Methods of Use | IMMUNOMEDICS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
| US-7563439-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2009-07-21 | — | — | US | disclosed |
| US-7560110-B2 | Production and use of novel peptide-based agents with bispecific antibodies | IMMUNOMEDICS, INC. (US) | 2009-07-14 | — | — | US | disclosed |
| US-7553953-B2 | Chimeric, human and humanized anti-CSAp monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7541440-B2 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | IMMUNOMEDICS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7534431-B2 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7521416-B2 | D-amino acid peptides | IMMUNOMEDICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7501498-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins | IMMUNOMEDICS, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20080293921-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | IMMUNOMEDICS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-7429381-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20080219920-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-7414121-B2 | Chimeric, human and humanized anti-CSAp monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2008-08-19 | — | — | US | disclosed |
| US-20080193451-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080193460-A1 | CHIMERIC, HUMAN AND HUMANIZED ANTI-CSAP MONOCLONAL ANTIBODIES | IMMUNOMEDICS, INC. | 2008-08-14 | — | — | US | disclosed |
| US-7405320-B2 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | IMMUNOMEDICS, INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20080146784-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | IMMUNOMEDICS, INC. (US) | 2008-06-19 | — | — | US | disclosed |
| US-7387772-B1 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNIMEDICS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| EP-1638510-A4 | MULTIVALENT CARRIERS OF BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS INC (US) | 2008-06-11 | — | — | EP | disclosed |
| US-20080089838-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | IMMUNOMEDICS, INC. | 2008-04-17 | — | — | US | disclosed |
| US-7300655-B2 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. (US) | 2007-11-27 | — | — | US | disclosed |
| US-20070183970-A1 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | IMMUNOMEDICS, INC. | 2007-08-09 | — | — | US | disclosed |
| US-20070142296-A1 | D-amino acid peptides | IMMUNOMEDICS, INC. | 2007-06-21 | — | — | US | disclosed |
| US-7230085-B2 | Complex of antibody and radionucleotide; therapy, medical diagnosis | IMMUNOMEDICS, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7172751-B2 | Immunological reagents for therapeutic use, for example, in radioimmunotherapy (RAIT), and diagnostic use, for example, in radioimmunodetection (RAID) and magnetic resonance imaging | IMMUNOMEDICS, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7138103-B2 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. (US) | 2006-11-21 | — | — | US | disclosed |
| EP-1720575-A2 | THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES | Immunomedics Inc. (US) | 2006-11-15 | — | — | EP | disclosed |
| EP-1372718-A4 | PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS INC (US) | 2006-10-18 | — | — | EP | disclosed |
| US-7074405-B1 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20060140858-A1 | Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) | IMMUNOMEDICS, INC. (US) | 2006-06-29 | — | — | US | disclosed |
| US-7052872-B1 | Bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| US-20060104899-A1 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| EP-1638510-A2 | MULTIVALENT CARRIERS OF BI-SPECIFIC ANTIBODIES | Immunomedics, Inc. (US) | 2006-03-29 | — | — | EP | disclosed |
| EP-1633773-A2 | D-AMINO ACID PEPTIDES | Immunomedics, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| US-20060034759-A1 | Production and use of novel peptide-based agents with bispecific antibodies | IMMUNOMEDICS, INC. (US) | 2006-02-16 | — | — | US | disclosed |
| US-6962702-B2 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS INC. (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1587550-A2 | METHODS AND COMPOSITIONS FOR ADMINISTERING THERAPEUTIC AND DIAGNOSTIC AGENTS | Immunomedics, Inc. (US) | 2005-10-26 | — | — | EP | disclosed |
| WO-2005077071-A2 | THERAPEUTIC AND DIAGNOSTIC CONJUGATES FOR USE WITH MULTISPECIFIC ANTIBODIES | IMMUNOMEDICS, INC. (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20050169926-A1 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | IMMUNOMEDICS, INC. (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005021494-A9 | D-AMINO ACID PEPTIDES | IMMUNOMEDICS INC (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1546204-A2 | HUMANIZED ANTI-GRANULOCYTE MN-3 ANTIBODY AND USES THEREOF | Immunomedics, Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050100543-A1 | Multivalent carriers of bi-specific antibodies | IMMUNOMEDICS, INC. (US) | 2005-05-12 | — | — | US | disclosed |
| WO-2005021494-A2 | D-AMINO ACID PEPTIDES | IMMUNOMEDICS, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-1506018-A1 | DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT(S) | Immunomedics, Inc. (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20050025709-A1 | D-amino acid peptides | IMMUNOMEDICS, INC. (US) | 2005-02-03 | — | — | US | disclosed |
| WO-2005004809-A2 | MULTIVALENT CARRIERS OF BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS, INC. (US) | 2005-01-20 | — | — | WO | disclosed |
| US-20050002945-A1 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | IMMUNOMEDICS, INC. | 2005-01-06 | — | — | US | disclosed |
| EP-1487879-A2 | BISPECIFIC ANTIBODY POINT MUTATIONS FOR ENHANCING RATE OF CLEARANCE | Immunomedics, Inc. (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040241158-A1 | Methods and compositions for administering therapeutic and diagnostic agents | IMMUNOMEDICS, INC. | 2004-12-02 | — | — | US | disclosed |
| US-20040235065-A1 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | IMMUNOMEDICS, INC. | 2004-11-25 | — | — | US | disclosed |
| WO-2004074434-A2 | METHODS AND COMPOSITIONS FOR ADMINISTERING THERAPEUTIC AND DIAGNOSTIC AGENTS | IMMUNOMEDICS, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| EP-1411987-A2 | TARGETED POLYMERIC DELIVERY SYSTEMS | Immunomedics, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| WO-2004029093-A2 | HUMANIZED ANTI-GRANULOCYTE MN-3 ANTIBODY AND USES THEREOF | IMMUNOMEDICS, INC. (US) | 2004-04-08 | — | — | WO | disclosed |
| US-20040043030-A1 | Polymeric delivery systems | IMMUNOMEDICS, INC. | 2004-03-04 | — | — | US | disclosed |
| US-20040018557-A1 | Bispecific antibody point mutations for enhancing rate of clearance | IMMUNOMEDICS, INC. | 2004-01-29 | — | — | US | disclosed |
| EP-1372718-A2 | PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES | Immunomedics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003097105-A1 | DRUG PRE-TARGETING BY MEANS OF BI-SPECIFIC ANTIBODIES AND HAPTEN CONSTRUCTS COMPRISING A CARRIER PEPTIDE AND THE ACTIVE AGENT (S) | IMMUNOMEDICS, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030198595-A1 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | IMMUNOMEDICS, INC. | 2003-10-23 | — | — | US | disclosed |
| WO-2003075010-A2 | NON-PEPTIDE IMMUNOLOGIC TRACER PRECURSORS COMPRISING A TYROSYL-(X)N OR LYSINE-(X)N TYROSINE MOTIF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE -CNRS- (FR) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003074569-A2 | BISPECIFIC ANTIBODY POINT MUTATIONS FOR ENHANCING RATE OF CLEARANCE | IMMUNOMEDICS, INC. (US) | 2003-09-12 | — | — | WO | disclosed |
| US-20030124057-A1 | Anti-DOTA antibody | IMMUNOMEDICS, INC. | 2003-07-03 | — | — | US | disclosed |
| WO-2003048207-A2 | ANTI-DOTA ANTIBODY | IMMUNOMEDICS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003011342-A2 | TARGETED POLYMERIC DELIVERY SYSTEMS | IMMUNOMEDICS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| US-20030026764-A1 | Polymeric delivery systems | IMMUNOMEDICS, INC. | 2003-02-06 | — | — | US | disclosed |
| WO-2002082041-A2 | PRODUCTION AND USE OF NOVEL PEPTIDE-BASED AGENTS FOR USE WITH BI-SPECIFIC ANTIBODIES | IMMUNOMEDICS, INC. (US) | 2002-10-17 | — | — | WO | disclosed |
| US-20020006379-A1 | Production and use of novel peptide-based agents for use with bi-specific antibodies | IMMUNOMEDICS, INC. | 2002-01-17 | — | — | US | disclosed |
| EP-1089766-A2 | USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS AND THERAPY | Immunomedics, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1007106-A1 | COMBINATORIAL LIBRARY | RESOLUTION PHARMACEUTICALS INC. (CA) | 2000-06-14 | — | — | EP | disclosed |
| WO-1999066951-A2 | USE OF BI-SPECIFIC ANTIBODIES FOR PRE-TARGETING DIAGNOSIS AND THERAPY | IMMUNOMEDICS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
| EP-0522004-B1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORP (US) | 1999-12-15 | — | — | EP | disclosed |
| WO-1999010016-A1 | COMBINATORIAL LIBRARY | RESOLUTION PHARMACEUTICALS INC. (CA) | 1999-03-04 | — | — | WO | disclosed |
| EP-0419387-B1 | Hydrophilic derivatives, diagnostic and therapeutic applications, kits and immunological reagents | IMMUNOTECH PARTNERS (FR) | 1996-11-20 | — | — | EP | disclosed |
| US-H1312-H | Method for the preparation of gyk-dtpa | CYTOGEN CORPORATION (US) | 1994-05-03 | — | — | US | disclosed |
| US-5274076-A | N-alpha-acetyl,N-epsilon(histamine-succinyl-glycl)-L-lysyl-L -tyrosyl-N-epsilon(histamine-succinyl-glycyl)-L-lysylamide | IMMUNOTECH PARTNERS (FR) | 1993-12-28 | — | — | US | disclosed |
| US-5256395-A | Drug delivery by administering a receptor binding assay having a dual preferential monoclonal antibody conjugating with predetermined haptens | IMMUNOTECH PARTNERS (FR) | 1993-10-26 | — | — | US | disclosed |
| EP-0522004-A1 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| US-5164367-A | Complexes with peptides | PROCYTE CORPORATION (US) | 1992-11-17 | — | — | US | disclosed |
| EP-0263046-B1 | AFFINITY ENHANCEMENT IMMUNOLOGICAL REAGENTS FOR DETECTION AND KILLING OF SPECIFIC TARGET CELLS | IMMUNOTECH PARTNERS (FR) | 1992-04-15 | — | — | EP | disclosed |
| WO-1991014437-A2 | USE OF COPPER(II) CONTAINING COMPOUNDS TO ACCELERATE WOUND HEALING | PROCYTE CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| US-5036052-A | Containing a dipeptide of tryptophan and alanine or lecine and no stabilizer; discoloration inhibition | MORISHITA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-30 | — | — | US | disclosed |
| EP-0419387-A1 | Hydrophilic derivatives, diagnostic and therapeutic applications, kits and immunological reagents | IMMUNOTECH PARTNERS: Société en Commandite par Actions dite (FR) | 1991-03-27 | — | — | EP | disclosed |
| EP-0347890-A1 | Amino acid nutrient compositions | Roussel Morishita Co., Ltd. (JP) | 1989-12-27 | — | — | EP | disclosed |
| EP-0326799-A2 | Enzymatic process for synthesizing peptides | Degussa Aktiengesellschaft (DE) | 1989-08-09 | — | — | EP | disclosed |
| EP-0263046-A1 | Affinity enhancement immunological reagents for detection and killing of specific target cells | IMMUNOTECH PARTNERS (FR) | 1988-04-06 | — | — | EP | disclosed |
| EP-0087751-B1 | WATER-SOLUBLE PEPTIDES FROM VERY POORLY SOLUBLE AMINO ACIDS | PFRIMMER KABI GMBH & CO. KG (DE) | 1985-05-29 | — | — | EP | disclosed |
| US-3953431-A | USEFUL FOR RADIOIMMUNOLOGICAL ASSAY OF DIGOXIN | BECTON, DICKINSON & COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
| US-3953431-A | USEFUL FOR RADIOIMMUNOLOGICAL ASSAY OF DIGOXIN | BECTON, DICKINSON & COMPANY (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (48 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246131-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | HRH3, BSG, HRH4 | LNPEP 89/4885ERAP2 1569/4885SLC7A5 1471/4885 |
| US-20060140858-A1 | Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) | MAN2B2, FUCA1, PREP | LNPEP 4/4885ERAP2 225/4885SLC7A5 2559/4885 |
| US-20020006379-A1 | Production and use of novel peptide-based agents for use with bi-specific antibodies | DNPEP, PA2G4, CD22 | LNPEP 13/4885ERAP2 311/4885SLC7A5 4054/4885 |
| US-20100196989-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | LNPEP 559/4885ERAP2 825/4885SLC7A5 4620/4885 |
| US-20120107235-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | LNPEP 559/4885ERAP2 825/4885SLC7A5 4620/4885 |
| US-20080146784-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | LNPEP 559/4885ERAP2 825/4885SLC7A5 4620/4885 |
| US-20230113836-A1 | NEW CONJUGATES OF PEPTIDES AND POLYSACCHARIDE | DSG1, HBG1, IDUA | LNPEP 799/4885ERAP2 4211/4885SLC7A5 1200/4885 |
| US-20100158802-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | LNPEP 46/4885ERAP2 131/4885SLC7A5 3296/4885 |
| US-20240173442-A1 | COMBINATION THERAPY | CD47, PAICS, CD22 | LNPEP 884/4885ERAP2 549/4885SLC7A5 3553/4885 |
| US-20060104899-A1 | Production and use of novel peptide-based agents for use with bi-specific antibodies | DNPEP, PA2G4, CD22 | LNPEP 13/4885ERAP2 311/4885SLC7A5 4054/4885 |
| US-12613191-B2 | Multiplexed Raman molecular imaging | FABP1, SCNN1G, VIL1 | LNPEP 2264/4885ERAP2 2818/4885SLC7A5 3612/4885 |
| US-20090238757-A1 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents | CD47, FCGR3B, HAVCR2 | LNPEP 383/4885ERAP2 1126/4885SLC7A5 3278/4885 |
| US-20030198595-A1 | Use of bi-specific antibodies for pre-targeting diagnosis and therapy | FCGR3B, FCGR2A, MAN2B2 | LNPEP 27/4885ERAP2 254/4885SLC7A5 3687/4885 |
| US-20090274649-A1 | Bispecific Antibody Point Mutations for Enhancing Rate of Clearance | FCGR3B, FCGR2A, FCGRT | LNPEP 88/4885ERAP2 2567/4885SLC7A5 912/4885 |
| US-20040018557-A1 | Bispecific antibody point mutations for enhancing rate of clearance | FCGR3B, FCGR2A, FCGRT | LNPEP 141/4885ERAP2 2511/4885SLC7A5 646/4885 |
| US-20230331792-A1 | NEW MULTI-FUNCTIONAL OLIGOPEPTIDES | VIP, MLX, IAPP | LNPEP 563/4885ERAP2 2651/4885SLC7A5 1900/4885 |
| US-11040108-B2 | Amino acid- and peptide-steroid conjugates and use thereof | NGLY1, CD81, MTX1 | LNPEP 41/4885ERAP2 1144/4885SLC7A5 145/4885 |
| US-20050002945-A1 | Therapeutic and diagnostic conjugates for use with multispecific antibodies | TST, GLUL, TGM3 | LNPEP 405/4885ERAP2 1620/4885SLC7A5 211/4885 |
| US-20050169926-A1 | Chimeric, human and humanized anti-CSAP monoclonal antibodies | CLSPN, CHP1, CACYBP | LNPEP 48/4885ERAP2 211/4885SLC7A5 2992/4885 |
| US-20220062371-A1 | LIGAND-DRUG-CONJUGATES AS SUBSTRATES FOR SELECTIVE CLEAVAGE BY THE EXOPEPTIDASE ACTIVITY OF CATHEPSIN B | CTSB, CTSE, CTSV | LNPEP 13/4885ERAP2 46/4885SLC7A5 324/4885 |
| US-20220389057-A1 | ENDOCYTOSIS ROUTING SEQUENCE PEPTIDE FOR CELL DELIVERY SYSTEMS | MARCKS, SORT1, PICALM | LNPEP 44/4885ERAP2 1324/4885SLC7A5 833/4885 |
| US-20060034759-A1 | Production and use of novel peptide-based agents with bispecific antibodies | FCGR3B, IGSF11, RNPEP | LNPEP 4/4885ERAP2 151/4885SLC7A5 3475/4885 |
| US-20110117010-A1 | Methods and Compositions for Administering Therapeutic and Diagnostic Agents | CD47, FCGR3B, HAVCR2 | LNPEP 383/4885ERAP2 1126/4885SLC7A5 3278/4885 |
| US-20070142296-A1 | D-amino acid peptides | DAO, NRDC, ARGLU1 | LNPEP 287/4885ERAP2 607/4885SLC7A5 8/4885 |
| US-20260109682-A1 | NOVEL COMPOUNDS AND THE USE FOR PROMOTING HAIR GROWTH OR INHIBITING INFLAMMATORY DISORDERS THEREOF | HSD3B1, HGF, HSD3B2 | LNPEP 4337/4885ERAP2 3431/4885SLC7A5 3186/4885 |
| US-20090252731-A1 | Multivalent Carriers of Bi-Specific Antibodies | FCGR3B, FCGR2A, FCGR1A | LNPEP 139/4885ERAP2 2767/4885SLC7A5 2256/4885 |
| US-20220267463-A1 | ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | CD47, CD4, CD99 | LNPEP 195/4885ERAP2 920/4885SLC7A5 1794/4885 |
| US-20110229407-A1 | Alpha-Fetoprotein Immu31 Antibodies and Fusion Proteins and Methods of Use Thereof | INHA, HDGF, IGSF11 | LNPEP 559/4885ERAP2 825/4885SLC7A5 4620/4885 |
| US-20070183970-A1 | Chimeric, human and humanized anti-granulocyte antibodies and methods of use | CSF3R, CCR3, FCGR3B | LNPEP 382/4885ERAP2 1758/4885SLC7A5 3495/4885 |
| US-20040235065-A1 | Alpha-fetoprotein Immu31 antibodies and fusion proteins and methods of use thereof | INHA, HDGF, IGSF11 | LNPEP 559/4885ERAP2 825/4885SLC7A5 4620/4885 |
| US-20080219920-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | LNPEP 46/4885ERAP2 131/4885SLC7A5 3296/4885 |
| US-20240082437-A1 | SPLIT ANTIBODIES WHICH BIND TO CANCER CELLS AND TARGET RADIONUCLIDES TO SAID CELLS | CD47, CD2, CD4 | LNPEP 239/4885ERAP2 875/4885SLC7A5 1770/4885 |
| US-20050025709-A1 | D-amino acid peptides | DAO, NRDC, ARGLU1 | LNPEP 287/4885ERAP2 607/4885SLC7A5 8/4885 |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | LNPEP 291/4885ERAP2 577/4885SLC7A5 3504/4885 |
| US-20080089838-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | LNPEP 46/4885ERAP2 131/4885SLC7A5 3296/4885 |
| US-20230173086-A1 | PEPTIDE CONJUGATES AND THERAPEUTIC AGENTS HAVING IMPROVED PHARMACOLOGICAL AND PHARMACOKINETIC PROPERTIES | VIP, DNPEP, CD74 | LNPEP 5/4885ERAP2 127/4885SLC7A5 728/4885 |
| US-20050100543-A1 | Multivalent carriers of bi-specific antibodies | FCGR3B, FCGR2A, FCGR1A | LNPEP 139/4885ERAP2 2767/4885SLC7A5 2256/4885 |
| US-20080293921-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | HRH3, BSG, HRH4 | LNPEP 30/4885ERAP2 683/4885SLC7A5 2150/4885 |
| US-20100202961-A1 | D-AMINO ACID PEPTIDES | ARGLU1, APLNR, NPBWR1 | LNPEP 290/4885ERAP2 625/4885SLC7A5 19/4885 |
| US-20110223645-A1 | Multivalent Carriers of Bi-Specific Antibodies | FCGR3B, FCGR2A, FCGR1A | LNPEP 139/4885ERAP2 2767/4885SLC7A5 2256/4885 |
| US-20100008855-A1 | Production and Use of Novel Peptide-Based Agents with Bispecific Antibodies | FCGR3B, IGSF11, RNPEP | LNPEP 4/4885ERAP2 151/4885SLC7A5 3475/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | LNPEP 291/4885ERAP2 577/4885SLC7A5 3504/4885 |
| US-20080193460-A1 | CHIMERIC, HUMAN AND HUMANIZED ANTI-CSAP MONOCLONAL ANTIBODIES | CHP1, CLSPN, CYTH3 | LNPEP 46/4885ERAP2 131/4885SLC7A5 3296/4885 |
| US-20100158803-A1 | Production and Use of Novel Peptide-Based Agents for Use with Bi-Specific Antibodies | HRH3, BSG, HRH4 | LNPEP 89/4885ERAP2 1569/4885SLC7A5 1471/4885 |
| US-20040241158-A1 | Methods and compositions for administering therapeutic and diagnostic agents | CD47, FCGR3B, HAVCR2 | LNPEP 383/4885ERAP2 1126/4885SLC7A5 3278/4885 |
| US-11576946-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | LNPEP 291/4885ERAP2 577/4885SLC7A5 3504/4885 |
| US-20090185974-A1 | Chimeric, Human and Humanized Anti-Granulocyte Antibodies and Methods of Use | CSF3R, CCR3, FCGR3B | LNPEP 382/4885ERAP2 1758/4885SLC7A5 3495/4885 |
| US-20080193451-A1 | Chimeric, Human and Humanized Anti-CSAP Monoclonal Antibodies | CHP1, CLSPN, CYTH3 | LNPEP 46/4885ERAP2 131/4885SLC7A5 3296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.